Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: A targeted therapy for liver cancer stem cells

Journal of Nanoparticle Research

Volumn 16, Issue 1, 2014, Pages

  Jin, Cheng ^a   Yang, Zhaoxu ^a   Yang, Jingyue ^a   Li, Haimin ^a   He, Yong ^a   An, Jiaze ^a   Bai, Ling ^b   Dou, Kefeng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Xi'An Xinxing Clinic   (China)

Author keywords

CD133; Liver cancer stem cells; Nanoparticles; Paclitaxel; Targeted delivery

Indexed keywords

CD133; EMULSIFICATION-SOLVENT EVAPORATIONS; ENCAPSULATION EFFICIENCY; LIVER CANCERS; PACLITAXEL; PHYSICOCHEMICAL CHARACTERISTICS; SPHERICAL MORPHOLOGIES; TARGETED DELIVERY;

ANTIBODIES; CELL CULTURE; DISEASES; EMULSIFICATION; ENCAPSULATION; MORPHOLOGY; PARTICLE SIZE ANALYSIS; STEM CELLS; TUMORS;

NANOPARTICLES;

CD133 ANTIGEN; NANOPARTICLE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CHEMISTRY; CONTROLLED STUDY; EMULSION; ENCAPSULATION; IN VITRO STUDY; LIVER CANCER; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; STEM CELL; TUMOR REGRESSION; XENOGRAFT;

EID: 84888812058     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-013-2157-5     Document Type: Article

References (37)

1. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649-1659
2. Chakraborty M, Jain S, Rani V (2011) Nanotechnology: emerging tool for diagnostics and therapeutics. Appl Biochem Biotechnol 165:1178-1187
3. Chen H, Gao J, Lu Y et al (2008) Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release 128:209-216
4. Chen R, Nishimura MC, Bumbaca SM et al (2010) A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17:362-375
5. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347-360
6. Filippov S, Hrubý M, Konák C et al (2008) Novel pH-responsive nanoparticles. Langmuir 24:9295-9301
7. Garvalov BK, Acker T (2011) Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med 89:95-107
8. Griffiths PC, Khayat Z, Tse S et al (2007) Studies on the mechanism of interaction of a bioresponsive endosomolytic polyamidoamine with interfaces. 1. Micelles as model surfaces. Biomacromolecules 8:1004-1012
9. Hashizume H, Baluk P, Morikawa S et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380
10. Hobbs SK, Monsky WL, Yuan F et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612
11. Jin C, Bai L, Wu H et al (2007a) Radiosensitization of paclitaxel, etanidazole and paclitaxel + etanidazole nanoparticles on hypoxic human tumor cells in vitro. Biomaterials 28:3724-3730
12. Jin C, Wu H, Liu J et al (2007b) The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. J Clin Pharm Ther 32:41-47
13. Jin C, Bai L, Wu H et al (2008) Paclitaxel-loaded poly(d,l-lactide-co- glycolide) nanoparticles for radiotherapy in hypoxic human tumor cells in vitro. Cancer Biol Ther 7:911-916
14. Jin C, Bai L, Wu H et al (2009) Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res 26:1776-1784
15. 2 for hepatocellular carcinoma. Biomacromolecules 11:2422-2431
16. Kirpotin DB, Drummond DC, Shao Y et al (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732-6740
17. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917
18. Ma S, Chan KW, Hu L et al (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542-2556
19. McDonald DM, Baluk P (2002) Significance of blood vessel leakiness in cancer. Cancer Res 62:5381-5385
20. Oishi N, Wang XW (2011) Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 7:517-535
21. Rahbari NN, Mehrabi A, Mollberg NM et al (2011) Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253:453-469
22. Richardson GD, Robson CN, Lang SH et al (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117:3539-3545
23. Scott CJ, Marouf WM, Quinn DJ et al (2008) Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles. Pharm Res 25:135-146
24. Smith LM, Nesterova A, Ryan MC et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100-109
25. Song W, Li H, Tao K et al (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62:1212-1218
26. Stephan MT, Moon JJ, Um SH et al (2010) Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 16:1035-1041
27. Suetsugu A, Nagaki M, Aoki H et al (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820-824
28. Swaminathan SK, Roger E, Toti U et al (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171:280-287
29. Takayama T (2011) Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol 41:447-454
30. Valencia PM, Hanewich-Hollatz MH, Gao W et al (2011) Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 32:6226-6233
31. Visvader JE (2011) Cells of origin in cancer. Nature 469:314-322
32. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768
33. Wagner S, Rothweiler F, Anhorn MG et al (2010) Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31:2388-2398
34. Wang X, Yang L, Chen ZG et al (2008) Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 58:97-110
35. Wang CH, Chiou SH, Chou CP et al (2011) Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 7:69-79
36. Yang ZH, Ho DW, Ng MN et al (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13:153-166
37. Yoo HS, Park TG (2001) Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 70:63-70